At 15.2% CAGR, Gout Therapeutics Market Size to Cross $ 9,815.6 million by 2026
Nov 13, 2019
MarketStudyReport.com Adds New Report Gout Therapeutics Market 2019 – 2026 research report providing information and data By Drug Class, By Disease Condition, By Region, Industry Analysis, Regional Outlook, Growth Potential, Competitive Market Share & Forecast spreading across 112 Pages with table and figures in it.
Delaware, Selbyville - November 13, 2019 /MarketersMedia/ —
NSAIDs, corticosteroids are among the approved drugs for treating gout condition and are available for purchase over the counter. These drugs are observed to be greatly effective in treating mild gout conditions and are expected to have significant impact on driving the growth in global gout therapeutics market. Moreover, rising preference for combination therapies due to benefits such as speeding up the treatment process, reduction in side effects is also another factor enhancing the market growth.
Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/1868592/?utm_source=Marketersmedia.com-AN
The incidence of gout has witnessed continual growth over the past years. It is majorly caused by uncontrolled metabolic disorder and high level of uric acid in the body. U.S. region is observed to have a high prevalence of gout owing to lifestyle issues such as high alcohol intake, obesity, and smoking resulting in the inflammatory disorder. Attributed to these factors along with the adoption of innovative treatments and increased understanding about arthritic conditions, the market in North America region is observed to be the dominant market across all regions during 2018. While, the Asia Pacific regional market is expected to witness highest growth rate owing to rising healthcare expenditure among the developing economies and significant investments by key players in this region.
The global gout therapeutics market is predicted to grow at a CAGR of 15.2% from 2019 to 2026 to reach USD 9,815.6 million by 2026, according to a new market report. The report Gout Therapeutics Market Size, Share, Trends & Analysis Report, By Drug Class (Urate-Lowering Agents, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs [NSAIDs], Colchicine); By Disease Condition (Chronic Gout, Acute Gout); By Region, Segment Forecast, 2019 - 2026 provides in depth analysis of the current and future market trends.
As per the severity of gout condition recommendations of medications and therapies are made to the respective patients. Multiple pharmaceutical companies have consistently increased the R&D investments to come up with further effective medications. The market for therapeutics of acute and chronic gout has witnessed significant growth over the past years and is expected to continue its growth trend. Although both segments are anticipated to grow, chronic gout segment presently holds major market share.
Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/1868592/?utm_source=Marketersmedia.com-AN
Some of the key players in this market are AstraZeneca, Horizon Pharma plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group. Companies are also increasingly having their focus on regenerative medicines which is further expected to contribute in the growth of gout therapeutics market.
Table of content:
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Global Gout Therapeutics Testing Market Insights
3.1. Gout Therapeutics Market ? Industry snapshot
3.2. Gout Therapeutics Market ? Ecosystem analysis
3.3. Gout Therapeutics Market ? Market dynamics
3.3.1. Gout Therapeutics Market ? Market Forces
3.3.1.1. Gout Therapeutics Market - Market driver analysis
3.3.1.2. Gout Therapeutics Market - Market restraint/challenges analysis
3.3.1.3. Gout Therapeutics Market - Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Gout Therapeutics Market PEST analysis, 2017
3.6. Value Chain Analysis
3.7. Gout Therapeutics Market Industry trends
4. Gout Therapeutics Market Size and Forecast by Drug Class
4.1. Key findings
4.2. Urate-Lowering Agents
4.3. Corticosteroids
4.4. Non-steroidal Anti-Inflammatory Drugs [NSAIDs]
4.5. Colchicine
5. Gout Therapeutics Market Size and Forecast by Disease Condition
5.1. Key findings
5.2. Chronic Gout
5.3. Acute Gout
6. Gout Therapeutics Market Size and Forecast by Regions
6.1. Key findings
6.2. North America
6.2.1. U.S.
6.2.2. Canada
6.3. Europe
6.3.1. Germany
6.3.2. UK
6.3.3. France
6.3.4. Italy
6.3.5. Spain
6.3.6. Belgium
Related Report:
Global Gout Therapeutics Market Size, Status and Forecast 2019-2025
Increased research and development in the field has yielded significantly more effective medications in the recent times, which are recommended to patients on the basis of severity of the condition. Introduction of urate-lowering agents is one of the primary driver of the gout therapeutics market. First line therapies such as Febuxostat and Allopurinol are now replaced urate-lowering agents such as Lesinurad, which help in reducing pain as well as negotiate the risk of joint destruction. The growing popularity of OTC drugs such as Oral colchicine, corticosteroids, and NASAIDs, which are quite effective in moderate gout indications, are also favoring the global gout therapeutics market in the positive direction. Technological advancements in medical imaging is another factor augmenting the demand in the gout therapeutics market. On the other hand, low levels of physician and patient awareness, heavy dependency on generic drugs, and use of CAM for the treatment of gout are restraining factors over the global gout therapeutics market.
Related Report: https://www.marketwatch.com/press-release/at-47-cagr-butyl-rubber-market-size-to-cross-5800-million-by-2024-2019-11-07
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Market Study Report LLC
Address: 4 North Main Street, Selbyville, Delaware 19975 USA
Phone: 1-302-273-0910
Website: https://www.marketstudyreport.com
Source URL: https://marketersmedia.com/at-152-cagr-gout-therapeutics-market-size-to-cross-98156-million-by-2026/88933944
Source: MarketersMedia
Release ID: 88933944
More News
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.